Roivant Sciences (ROIV) Reports Positive Phase 3 Data for Brepocitinib in Dermatomyositis, Plans NDA Filing in Early 2026
Roivant Sciences (ROIV) disclosed positive Phase 3 data for brepocitinib in dermatomyositis and a $4.4 billion cash position in an SEC 8-K filing.